Chris Myatt, PhD Founder and Chief Executive Officer
Chris Myatt is the founder and CEO of MBio Diagnostics, Inc. Prior to MBio Diagnostics, Chris founded and led Precision Photonics Corporation, a successful laser and optical technology supplier that is now a division of IDEX. Trained as a physicist and measurement scientist, Chris invented and developed multiple technologies that formed the basis of his companies. He studied Bose-Einstein Condensation (BEC) under Carl Wieman (Nobel Prize, 2001), helping to create the first BEC condensate in the Wieman lab. He also studied quantum information under David Wineland (Nobel Prize, 2012) as a National Research Council (NRC) Postdoctoral Fellow at the National Institute of Standards and Technology (NIST) in Boulder.
Byron Hewett, MBA President, Brava Diagnostics
Byron Hewett has led healthcare and life science companies for more than 30 years, in multi-national firms, development-stage and start-up companies. Byron is a 4-time CEO, including Brava Diagnostics. Prior to Brava, Byron was CEO of SomaLogic, a life sciences tools company focused on biomarker discovery. He served as Chairman and CEO of BioBehavioral Diagnostics, a start-up medical device company with the first FDA-cleared system for the assessment of ADHD. He served as CEO and a director at Immunicon (NASDAQ: IMMC), the first FDA-cleared test for circulating tumor cells. He served in executive roles at Qiagen, Bayer Diagnostics, Chiron Diagnostics and Abbott.
Byron earned a Masters in Management from Northwestern University’s J.L. Kellogg Graduate School of Management and a Bachelor’s of Science degree from the University of Virginia’s McIntire School of Commerce.
Mike Lochhead, PhD Chief Operating Officer
Mike Lochhead has been with MBio since it was founded. Mike is a technical business executive focused on development and commercialization of life science and medical diagnostic products. He provides leadership in IP strategy, operations, R&D management, organizational growth, and fundraising within startup organizations. Mike has a record of identifying, establishing, and managing programs with strategic partners and clinical collaborators.
Dave Okrongly, PhD Chief Science Officer
Dave Okrongly has been a business executive and R&D leader in the diagnostics industry, ranging from start-up to multi-national companies. He brings expertise in instrument and assay development, clinical/regulatory affairs and operations. Prior to joining Brava, Dave served as President of the OPKO Diagnostics division of OPKO Health, Inc. (NASDQ: OPK). He led the development and launch of the 4Kscore test for aggressive prostate cancer risk determination, and the development of the FDA-approved Claros 1 point-of-care analyzer. He served as chief operating officer of Exosome Diagnostics, President and CEO for Quanterix Corporation (NASDQ: QTRX), and held leadership positions with Siemens and Bayer Diagnostics.
Carrie Mulherin, MBA Chief Marketing Officer
Carrie Mulherin is a marketing and sales executive with extensive start-up experience and 31 product launches. Carrie brings deep experience in strategic marketing, cross-functional team management and commercialization. Carrie was CEO of Focus Marketing, an independent consulting agency, VP of Diagnostics at SomaLogic, VP of Marketing and Sales for BioBDx/Pearson, Director of Marketing for Orasure Technologies, VP of Marketing and Sales at Immunicon Corporation and VP Sales and Marketing at Intracel Corporation.
Kenny Edwards Chief Financial Officer
Kenny Edwards is an experienced, entrepreneurial CFO with over 25 years of diverse expertise in private and public company financial leadership. Kenny served as CFO for CenterStone Technologies, Inc., a privately held SaaS technology organization. Mr. Edwards led CenterStone’s successful 2018 acquisition. During his tenure, the organization identified, acquired and merged two organizations; one in the US and one in France.
Nick Traggis VP, Corporate Development
Nick Traggis brings a strong deal-making expertise to our team as well as an ability to strategically evaluate current and emerging opportunities. Most recently, he has served as a consultant performing C-level directed projects in areas of technology transfer, contract negotiation, and mergers/acquisitions for high-tech manufacturing companies. Prior to that he worked as the General Manager of Precision Photonics; ultimately selling to IDEX Corporation, where he remained on as the Chief Technology Officer.
Sally Hatcher, JD Corporate Secretary
Sally Hatcher is a serial entrepreneur, advisor, start-up accelerator faculty member, impact investor and board member. She regularly consults with diverse teams of innovators looking to spinout or start up a company.